Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Tianyu Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3719-1459; OpenAlex author ID A5100379435. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
12
Papers, trials and grants by year

2022: 3 papers · 2023: 4 papers · 2024: 2 papers · 2025: 1 paper

Papers 10

  1. Global, regional, and national burden of pancreatic cancer from 1990 to 2021, its attributable risk factors, and projections to 2050: a systematic analysis of … Co-author DOI 10.1186/s12885-025-13597-z↗
  2. Extracellular vesicles miR-31-5p promotes pancreatic cancer chemoresistance via regulating LATS2-Hippo pathway and promoting SPARC secretion from pancreatic st… Co-author DOI 10.1002/jev2.12488↗
  3. The systematic role of pancreatic cancer exosomes: distant communication, liquid biopsy and future therapy. First author DOI 10.1186/s12935-024-03456-5↗
  4. STOML2 restricts mitophagy and increases chemosensitivity in pancreatic cancer through stabilizing PARL-induced PINK1 degradation. Co-author DOI 10.1038/s41419-023-05711-5↗
  5. EGR1 induces EMT in pancreatic cancer via a P300/SNAI2 pathway. Co-author DOI 10.1186/s12967-023-04043-4↗
  6. Pancreatic cancer stemness: dynamic status in malignant progression. Co-author DOI 10.1186/s13046-023-02693-2↗
  7. DHX38 restricts chemoresistance by regulating the alternative pre-mRNA splicing of RELL2 in pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pgen.1010847↗
  8. CHRNB2 represses pancreatic cancer migration and invasion via inhibiting β-catenin pathway. Co-author DOI 10.1186/s12935-022-02768-8↗
  9. Multidrug resistance genes screening of pancreatic ductal adenocarcinoma based on sensitivity profile to chemotherapeutic drugs. Co-author DOI 10.1186/s12935-022-02785-7↗
  10. Multidrug resistance genes screening of pancreatic cancer based on sensitivity profile to chemotherapeutic drugs Co-author DOI 10.21203/rs.3.rs-1759071/v2↗

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Weibin Wang · 8 shared papers, 2022–2025 · strength 1.76
  2. Bangbo Zhao · 9 shared papers, 2022–2024 · strength 1.73
  3. Zeru Li · 9 shared papers, 2022–2024 · strength 1.73
  4. Yutong Zhao · 7 shared papers, 2022–2024 · strength 1.41
  5. Yuanyang Wang · 7 shared papers, 2022–2023 · strength 1.26
  6. Cheng‐Feng Qin · 6 shared papers, 2022–2024 · strength 1.15
  7. Xiaoying Yang · 6 shared papers, 2022–2023 · strength 1.05
  8. Tianhao Li · 3 shared papers, 2022 · strength 0.47
  9. Weibin Wang · 2 shared papers, 2023 · strength 0.39
  10. Cheng Yong Qin · 2 shared papers, 2022–2024 · strength 0.39
  11. Yupei Zhao · 1 shared paper, 2024 · strength 0.23
  12. Cheng Qin · 1 shared paper, 2023 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.